An EUA for bamlanivimab and etesevimab for COVID-19.

Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2021

Data sources: Europe PubMed Central

An EUA for bamlanivimab and etesevimab for COVID-19.

descriptionPublicationkeyboard_double_arrow_right Article 14 Apr 2021 English Journal:The Medical letter on drugs and therapeutics, volume 63 (issn: 1523-2859,

Copyright policy )

pmid: 33830966

An EUA for bamlanivimab and etesevimab for COVID-19.

- Summary
- Subjects
- Metrics

No summary information available

Keywords

SARS-CoV-2, United States Food and Drug Administration, COVID-19, Antibodies, Monoclonal, Humanized, Antiviral Agents, Antibodies, Neutralizing, United States, COVID-19 Drug Treatment, Treatment Outcome, Humans, Drug Approval

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average